Câncer de Pulmão Online (Lung cancer)

■ Câncer de pulmão: dados de três anos do registro hospitalar de câncer de um hospital do sul do Brasil

I P Giacomelli, L J M Steidle, I L Giacomelli et al

Arquivos Catarinenses de Medicina 2017, vol 46 (3)

http://www.acm.org.br/acm/seer/index.php/arquivos/article/view/314/195

■ Is endobronchial ultrasound-guided transbronchial needle aspiration with a stylet necessary for lymph node screening in lung cancer patients?

Xu, Y. et al.

Braz J Med Biol Res, 2017, vol.50, no.10

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017001000606&lng=en&nrm=iso

■ Residential radon and lung cancer: a cohort study in Galicia, Spain

Barbosa-Lorenzo, Raquel et al.

Cad. Saúde Pública, 2017, vol.33, no.6.

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2017000605007&lng=en&nrm=iso&tlng=en

■ Refractory lactic acidosis in small cell carcinoma of the lung

Daniel J. Oh, Ellen Dinerman, Andrew H. Matthews, Abraham W. Aron, Katherine M. Berg

Case Rep Crit Care. 2017; 2017: 6148350

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460431/

■ Progress and prospects of early detection in lung cancer

Sean Blandin Knight, Phil A. Crosbie, Haval Balata et al

Open Biol. 2017 Sep; 7(9): 170070

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627048/

■ Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy

Roberto Chalela, Víctor Curull, César Enríquez, et AL

J Thorac Dis. 2017, vol 9(7): 2142–2158

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542927/

■ Physical activity and sedentary behavior in relation to lung câncer incidence and mortality in older women: The Women´s Health Initiative

Ange Wang, FeiFei Qin, Haley Hedlin et al

Int J Cancer. 2016, vol 139(10): 2178–2192

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501309/

■ Psychological burden associated with lung cancer screening: a systematic review

Geena X. Wu, Dan J. Raz, Laura Brown, Virginia Sun

Clin Lung Cancer. 2016 Sep; 17(5): 315–324

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606246/

■ Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer

S L Pruitt, A L Laccetti, D E Gerber

British Journal of Cancer 2017, vol 116: 717-725

https://www.nature.com/articles/bjc201727

■ Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis on non-small-cell lung cancer

M Alexander, R Wolfe, S M Evans

British Journal of Cancer 2017, vol 117: 744-751

https://www.nature.com/articles/bjc2017232

■ Stereotactic body radiotherapy for early-stage non-small-cell lung cancer

American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline

B J Schneider, M E Daly, E B Kennedy et al

Journal of Clinical Oncology 2017

http://ascopubs.org/doi/full/10.1200/JCO.2017.74.9671

■ Genomic profiling of early-stage lung cancer for patterns of recurrence

C A DiPema, L Fine

Journal of Clinical Oncology may 2017

http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e23126

■ Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers

A E Drilon, T Filleron, I Bergagnini et al

Journal of Clinical Oncology may 2017

http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9069

■ Evolution and increasing complexity of the therapeutic landscape in advanced non-small-cell lung cancer

D R Gandara, J W Riess, K Kelly et al

Clin Lung Cancer. 2016 Sep; 18(1): 1-4

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30387-4/fulltext

■ Immunotherapy comes of age in lung cancer

P Khanna, N Blais, P Gaudreau, L Corrales-Rodrigues

Clin Lung Cancer. 2017 Sep; 18(1): 13-22

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30146-2/fulltext

■ Intercalated chemotherapy and epidermal growth factor receptor inhibitors for patient with advanced non-small-cell lung cancer: a systematic review and meta-analysis

A La Salvia, A Rossi, D Galetta et AL

Clin Lung Cancer. 2017 Sep; 18(1): 13-22

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30240-6/fulltext

■ Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and ooportunities

M E Gutierrez, K Choi, R B Lanman et al

Clin Lung Cancer. 2017 Sep; 18(6): 651-659

http://www.clinical-lung-cancer.com/article/S1525-7304(17)30109-2/fulltext

■ Prognostic role of the FGFR4-388Arg variant in lung squamous-cell carcinoma patients with lymph node involvement

A Quintanal-Villalonga, A Carranza-Carranza, R Meléndez et AL

Clin Lung Cancer. 2017 , vol 18(6): 667-674.e1

http://www.clinical-lung-cancer.com/article/S1525-7304(17)30143-2/fulltext

■ Comparison of radiotherapy and chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer developing after surgery

S Nakamichi, H Horinouchi, T Asao et al

Clin Lung Cancer. 2017, vol 18(6): e441-e448

http://www.clinical-lung-cancer.com/article/S1525-7304(17)30140-7/fulltext

■ Evaluating the genomic yield of a singleendobronchial ultrasound-guided transbronchial needle aspiration in lung cancer: meeting the challenge of doing more with less

T L Leong, M Christie, S Kranz et al

Clin Lung Cancer. 2017, vol 18(6): e467-e472

http://www.clinical-lung-cancer.com/article/S1525-7304(17)30141-9/fulltext

■ Long-term outcomes of induction carboplatin and gemcitabine followed by concurrent radiotherapy with low-dose paclitaxel and gemcitabine for stage III non-small-cell lung cancer

C Guilbault, A Garant, S Faria et al

Clin Lung Cancer. 2017, vol 18(6): 565-571

http://www.clinical-lung-cancer.com/article/S1525-7304(17)30046-3/fulltext

■ Stereotactic body radiotherapy for large (> 5 cm) non-small cell lung cancer

J Peterson, C Niles, A Patel et al

Clin Lung Cancer. 2017, vol 18(4): 396-400

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30374-6/fulltext

■ Assessing PDL-1 and PD-1 in non-smal cell lung cancer: a noval immunoscore approach

E Paulsen, T K Kivaer, M R Khanehkenari et AL

Clinical Lung Cancer 2017, vol 18 (2): 220-233.e8

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30235-2/fulltext

■ Phase 2 study of erlotinib in combination with linsitinib (OSI-906) or placebo in chemotherapy-naïve patients with non-small-cell lung cancer and activating epidermal growth factor receport mutations

N B Leighl, N A Rizvi, L G de Lima Jr et al

Clinical Lung Cancer 2017, vol 18 (1): 34-42.e2

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30187-5/fulltext

■ Efficacy and safety results from a phase II, placebo-controlled study of onartuzumab plus first-line platinum-doublet chemotherapy for advanced squamous cell non-small-cell lung cancer

F R Hirsch, R Govindan, Z Zvirbule et AL

Clinical Lung Cancer 2017, vol 18 (1): 43-49

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30116-4/fulltext

■ Efficacy and safety of onartuzumab in combination with first-line bevacizumab-or pemetrexed-based chemotherapy regimens in advanced non-squamous non-small-cell lung cancer

H Wakelee, Z Zvirbule, P De Braud et al

Clinical Lung Cancer 2017, vol 18 (1): 50-59

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30241-8/fulltext

■ Phase ½ study of the CD56-targeting antibody-drug conjugate loryotuzumab mertansine 9IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease

M A Socinski, F J Kaye, D R Spigel et al

Clinical Lung Cancer 2017, vol 18 (1): 68-76.e2

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30227-3/fulltext

■ Effect of accurate staging using positron emission tomography on the outcomes of prophylactic cranial irradiation in patients with limited stage small-cell lung cancer

M Choi, Y Lee, S H Moon et al

Clinical Lung Cancer 2017, vol 18 (1): 77-84

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30178-4/fulltext

■ Treatment rationale and study design for the RELAY Study: a multicenter, randomized, double-blind study of erlotinib with ramucirumab or placebo in patients with epidermal growth factor receptor mutation-positive metastatic non-smal-cell lung cancer

E B Garon, M Reck, L Paz-Ares et al

Clinical Lung Cancer 2017, vol 18 (1): 96-99

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30139-5/fulltext

■ Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic process

A J Murton, M Maddocks, F B Stephens et al

Clinical Lung Cancer 2017, vol 18 (1): e1-e11

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30143-7/fulltext

■ Outcomes of elderly patients who receive combined modality therapy for locally advanced non-smal-cell lung cancer

M Zaki, M Dominello, G Dyson et al

Clinical Lung Cancer 2017, vol 18 (1): e1-e11

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30185-1/fulltext

■ Cost of diagnostic assessment for lung cancer: a medicare claims analysis

T Lokhandwala, M A Bittoni, R A Dann et al

Clinical Lung Cancer 2017, vol 18 (1): e27-e34

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30186-3/fulltext

■ Survical of Asian females with advanced lung cancer in the era of tyrosine kinase inhibitor therapy

D J Becker, J P Wisnivesky, M L Grossbarde et al

Clinical Lung Cancer 2017, vol 18 (1): e35-40

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30243-1/fulltext

■ A cost-effectiveness analysis of using the JBR.10-based 15-gene expression signature to guide adjuvant chemotherapy in early stage non-small-cell lung cancer

K M Wong, K Ding, S Li et al

Clinical Lung Cancer 2017, vol 18 (1): e41-e47

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30149-8/fulltext

■ Patterns of distant metastases after surgical management on non-small-cell lung cancer

J A Torok, L Gu, D J Tandberg et al

Clinical Lung Cancer 2017, vol 18 (1): e57-e70

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30169-3/fulltext

■ Challenges in facing the lung cancer epidemic and treating advanced disease in Latin America

L E Raez, E S Santos, C Rolfo et AL

Clinical Lung Cancer 2017, vol 18 (1): e71-e79

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30108-5/fulltext

■ Successful use of afatinib after erolotinib-induced pneumonitis in a patient with epidermal growth factor receptor-mutant lung cancer

C D Jakubowski, A J Plodkowski, J C Chang et al

Clinical Lung Cancer 2017, vol 18 (1): e81-e83

http://www.clinical-lung-cancer.com/article/S1525-7304(16)30344-8/fulltext

■ Exposure-response analyses of asbestos and lung cancer subtypes in a pooled analysis of case-control studies

Ann C. Olsson, Roel Vermeulen, Joachim Schüz et al

Epidemiology. 2017, vol 28(2): 288–299

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287435/

■ Brochoalveolar lavage protemomics in patients with suspected lung cancer

Ana Sofia Carvalho, Célia Marina Cuco, Carla Lavareda et al

Sci Rep. 2017; vol 7: 42190.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294405/

■ The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics

Ting-Yuan David Cheng, Susanna M. Cramb, Peter D. Baade et al

J Thorac Oncol. 2016 Oct; 11(10): 1653–1671

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512876/

■ Smal cell lung cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?

Paul A. Bunn, Jr, John Minna, Alexander Augustyn et al

J Thorac Oncol. 2016 Apr; 11(4): 453–474

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836290/

■ Pairing smoking-cessation services with lung cancer screening: a clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco

Lisa M. Fucito, Sharon Czabafy, Peter S. Hendricks et al

Cancer. 2016; vol 122(8): 1150–1159

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828323/

■ Recommendations on screening for lung cancer

Canadian Task Force on Preventive Health Care

CMAJ 2016, vol 188: 425-432

http://www.cmaj.ca/content/188/6/425.full

■ Chemotherapy for advanced non-small cell lung cancer in the elderly population

Santos, Fábio Nasser et al.

Sao Paulo Med. J., Oct 2016, vol.134, no.5, p.465-466

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802016000500465&lng=en&nrm=iso

■ Lung cancer screening

L T Tanoue, N T Tanner, M K Gould, G A Silvestri

AJRCCM 2015, vol 191(1)

http://www.atsjournals.org/doi/full/10.1164/rccm.201410-1777CI

■ Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study

Swaantje Casjens, Daniel G Weber, Georg Johnen et al

BMJ Open. 2017; 7(10): e017104

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652464/

■ The utility of exercise testing in patient with lung cancer

Duc Ha, Peter J. Mazzone, Andrew L. Ries, Atul Malhotra, Mark Fuster

J Thorac Oncol. 2016 Sep; 11(9): 1397–1410

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483326/

■ Sobrecarga do cuidador familiar: a sobrecarga de cuidar de pacientes com câncer de pulmão, de acordo com o estágio do câncer e a qualidade de vida do paciente

Borges, Eliana Lourenço et al.

bras. pneumol., Feb 2017, vol.43, no.1, p.18-23

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132017000100018&lng=en&nrm=iso&tlng=pt

■ Avaliação da fadiga utilizando a Escala de Identificação e Consequências da Fadiga em pacientes com câncer de pulmão.

Nogueira, Ingrid Correia et al.

bras. pneumol., June 2017, vol.43, no.3, p.169-175

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132017000300169&lng=en&nrm=iso&tlng=pt

■ Estimativa dos custos da assistência do câncer de pulmão avançado em hospital público de referência.

Knust, Renata Erthal et al.

Rev. Saúde Pública, 2017, vol.51

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102017000100264&lng=en&nrm=iso&tlng=pt

■ Revealing potential long non-coding RNA biomarkers in lung adenocarcinoma using long non-coding RNA-mediated competitive endogenous RNA network

Zhu, T-G. et al.

Braz J Med Biol Res, 2017, vol.50, no.9

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000900606&lng=en&nrm=iso

■ Is endobronchial ultrasound-guided transbronchial needle aspiration with a stylet necessary for lymph node screening in lung cancer patients?

Xu, Y. et al.

Braz J Med Biol Res, 2017, vol.50, no.10

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017001000606&lng=en&nrm=iso

■ The diagnostic value of narrow-band imaging for early and invasive lung cancer: a meta-analysis

Zhu, Juanjuan et al.

Clinics, July 2017, vol.72, no.7, p.438-448

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322017000700438&lng=en&nrm=iso

■ Successes and failures: What did we learn from recent first-line treatment immunotherapy trials in non-smal cell lung câncer?

Jordi Remon, Benjamin Besse, Jean-Charles Soria

BMC Med. 2017; 15: 55.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346853/

■ Utilização de cateter pleural de longa permanência para o tratamento definitivo de derrame pleural neoplásico.

Abrão, Fernando Conrado et al.

bras. pneumol., Feb 2017, vol.43, no.1, p.14-17

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132017000100014&lng=pt&nrm=iso&tlng=pt

■ Posicionamento intrapleural, guiado por ultrassonografia, de cateteres pleurais: influência na expansão pulmonar imediata e na pleurodese em pacientes com derrame pleural maligno recorrente

Araujo, Pedro Henrique Xavier Nabuco de et al

bras. pneumol., June 2017, vol.43, no.3, p.190-194

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132017000300190&lng=pt&nrm=iso&tlng=pt

■ Tendência das taxas de mortalidade de câncer de pulmão corrigidas no Brasil e regiões.

Malta, Deborah Carvalho et a

Rev. Saúde Pública, 2016, vol.50

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102016000100224&lng=en&nrm=iso&tlng=pt
■ Fatores associados à sobrevida doença-específica em pacientes com câncer de pulmão de células não pequenas.

Souza, Mirian Carvalho de, Cruz, Oswaldo Gonçalves and Vasconcelos, Ana Glória Godoi

bras. pneumol., Oct 2016, vol.42, no.5, p.317-325

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132016000500317&lng=en&nrm=iso&tlng=pt

■ PET/CT used in the evaluation of pulmonary nodules suspicious for lung cancer in regions where infectious lung disease is endemic: to be or not to be?.

Hochhegger, Bruno.

Radiol Bras, June 2016, vol.49, no.3, p.199-199

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842016000300013&lng=en&nrm=iso

■ Nódulo pulmonar solitário e ¹⁸F-FDG PET/CT. Parte 1: epidemiologia, avaliação morfológica e probabilidade de câncer

Mosmann, Marcos Pretto et al.

Radiol Bras, Feb 2016, vol.49, no.1, p.35-42

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842016000100035&lng=en&nrm=iso&tlng=pt

■ Nódulo pulmonar solitário e ¹⁸F-FDG PET/CT. Parte 2: acurácia, custo-efetividade e recomendações atuais.

Mosmann, Marcos Pretto et al.

Radiol Bras, Apr 2016, vol.49, no.2, p.104-111

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-39842016000200011&lng=en&nrm=iso&tlng=pt

■ Effects of lung cancer cell-associated B7-H1 on T-cell proliferation in vitro and in vivo

Chen, K. et al.

Braz J Med Biol Res, 2016, vol.49, no.7

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000700701&lng=en&nrm=iso

■ Analysis of Pd-L1 expression in non-small cell lung cancer microenvironments and its role as a potential predictive biomarker

M C L Santos, M Y Kadekaru, R K de Souza et al

Medicina USP 2016, vol 95 (2)

http://www.revistas.usp.br/revistadc/article/view/115740/119963

■ Impacto do F-FDG/PET/CT no estadiamento de pacientes com câncer de pulmão: chave para melhorar o tratamento

G O Bretas, J B Guedes, F M C Carvalho et al

Rev Med Minas Gerais 2016, vol 26: e1789

http://www.rmmg.org/artigo/detalhes/2070

■ 31 years of lung câncer in the canton of Zurich, Switzerland: incidence trends by sex, histology and laterality

L S Oberli, F Valeri, S Rohrmann, S Dehler

Swiss Med Wkly 2016, vo 146:w14327

https://smw.ch/en/article/doi/smw.2016.14327/

■ Significance of coexistent granulomatous inflammation and lung cancer

Rucha S Dagaonkar, Caroline V Choong, Atasha Binti Asmat, et al

J Clin Pathol. 2017 Apr; 70(4): 337–341

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484024/

■ Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomized controlled trial

Kate Brain, Kate J Lifford, Ben Carter et al

Thorax. 2016 Nov; 71(11): 996–1005

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099188/

■ Managing interstitial lung disease detected on CT during lung câncer screening

B D Southern R G Scheraga, R Yadav

Cleveland Clinic Journal of Medicine 2016, vol 83 (1): 55-65

http://www.mdedge.com/ccjm/article/105368/imaging/managing-interstitial-lung-disease-detected-ct-during-lung-cancer

■ Impacto orçamentário da incorporação da tomografia de emissão de pósitrons – tomografia computadorizada para estadiamento de câncer pulmonar

Biz, Aline Navega and Caetano, Rosângela

Rev. Saúde Pública, 2015, vol.49

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102015000100305&lng=en&nrm=iso&tlng=pt

■ American Cancer Society lung cancer screening guidelines

Richard Wender, Elizabeth T. H. Fontham, Ermilo Barrera et al

CA Cancer J Clin. 2013 Mar-Apr; 63(2): 107–117

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632634/

■ Biomarkers for screening of lung cancer and pre-neoplastic lesions in a high risk Chilean population

Adonis, Marta I et al.

Biol. Res., 2014, vol.47, p.1-9

http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602014000100056&lng=en&nrm=iso

■ Computed tomography screening for lung cancer: Has it finally arrived? Implications of the National Lung Screening Trial

D R Aberle, F Abtin, K Brown

Journal of Clinical Oncology mar 2013

http://ascopubs.org/doi/full/10.1200/JCO.2012.43.3110

■ Screening and early detection of lung cancer

S C van´t Westeinde, R J van Klaveren

The Cancer Journal 2011, vol 17 (1): 3-10

http://journals.lww.com/journalppo/Fulltext/2011/01000/Screening_and_Early_Detection_of_Lung_Cancer.2.aspx

■ Lung cancer: diagnosis, treatment principles, and screening

K M Latimer, T F Mott

Am Fam Physician 2015, vol 91 (4): 250-256

http://www.aafp.org/afp/2015/0215/p250.html

■ Systemic therapy for stabe IV non-small-cell lung cancer

N Hanna, D Johnson, S Temin et al

American Society of Clinical Oncology Clinical Practive Guideline Update

Journal of Clinical Oncology oct 2017

http://ascopubs.org/doi/full/10.1200/JCO.2017.74.6065

■ The real-world experience with nivolumab in previously treated patients with advanced non small cell lung cancer (NSCLC): A Galician Lung Cancer Group Clinical Practice

M C Areses, R G Campelo, J G González et al

Journal of Clinical Oncology may 2017

http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e20564

■ A study of rovalpituzumab tesirine in frontline treatment of patients with DLL3 expressing extensive small cell lung cancer

C L Hann, D Morgensztern, A Dowlati et al

Journal of Clinical Oncology may 2017

http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS2598

■ A phase III study of rovalpituzumab tesirine maintenance therapy following first-line platinum-based chemotherapy in patients with extensive disease small cell lung cancer (ED SCLC)

P B Komamitsky, H Lee, M Shah et al

Journal of Clinical Oncology may 2017

http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS8583

■ A phase 1 study of osimertinib and bevacizumab as initial treatment for patients with EGFR-mutant lung cancers

H A Yu, S A Hayes, R J Young et al

Journal of Clinical Oncology may 2017

http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9033

■ Mechanisms of resistance to EGFR-targeted drugs: lung cancer

F Morgillo, C M D Corte, M Fasano et AL

ESMO Open 2016, vol 1 (3): e000060

http://esmoopen.bmj.com/content/1/3/e000060

■ Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets